CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 68 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $1,644,000 | -34.1% | 152,943 | -7.5% | 0.00% | -50.0% |
| Q4 2018 | $2,496,000 | -59.8% | 165,302 | -50.7% | 0.00% | 0.0% |
| Q3 2018 | $6,204,000 | +12.6% | 335,352 | +39.2% | 0.00% | -50.0% |
| Q2 2018 | $5,508,000 | -7.7% | 240,928 | +14.8% | 0.00% | 0.0% |
| Q1 2018 | $5,969,000 | +33.4% | 209,801 | -1.1% | 0.00% | +33.3% |
| Q4 2017 | $4,476,000 | +3.6% | 212,047 | -10.8% | 0.00% | 0.0% |
| Q3 2017 | $4,319,000 | +64.3% | 237,699 | +40.2% | 0.00% | +50.0% |
| Q2 2017 | $2,628,000 | +154.7% | 169,552 | +183.7% | 0.00% | +100.0% |
| Q1 2017 | $1,032,000 | +42.5% | 59,761 | -9.3% | 0.00% | 0.0% |
| Q4 2016 | $724,000 | -30.1% | 65,902 | -0.3% | 0.00% | 0.0% |
| Q3 2016 | $1,036,000 | +52.8% | 66,088 | -0.4% | 0.00% | 0.0% |
| Q2 2016 | $678,000 | +205.4% | 66,368 | +285.6% | 0.00% | – |
| Q1 2016 | $222,000 | -38.2% | 17,210 | 0.0% | 0.00% | – |
| Q4 2015 | $359,000 | – | 17,210 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 5,803,700 | $25,130,000 | 0.91% |
| Altium Capital Management LP | 663,800 | $2,874,000 | 0.79% |
| Rubric Capital Management LP | 2,406,449 | $10,420,000 | 0.49% |
| RTW INVESTMENTS, LP | 6,029,700 | $26,109,000 | 0.38% |
| Orbimed Advisors | 3,214,509 | $13,919,000 | 0.18% |
| TANG CAPITAL MANAGEMENT LLC | 152,345 | $660,000 | 0.13% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 980,085 | $4,244,000 | 0.12% |
| Point72 Asset Management, L.P. | 6,303,025 | $27,292,000 | 0.11% |
| Sender Co & Partners, Inc. | 40,720 | $176,000 | 0.09% |
| Manteio Capital LLC | 15,067 | $65,000 | 0.08% |